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Summary
Malaria is a scourge of large swathes of the globe,
stressing the need for a continuing effort to better
understand the biology of its aetiological agent. Like
all pathogens of the phylum Apicomplexa, the malaria
parasite spends part of its life inside a host cell or
cyst. It eventually needs to escape (egress) from this
protective environment to progress through its life
cycle. Egress of Plasmodium blood-stage merozoites,
liver-stage merozoites and mosquito midgut sporo-
zoites relies on protease activity, so the enzymes
involved have potential as antimalarial drug targets.
This review examines the role of parasite proteases in
egress, in the light of current knowledge of the
mechanics of the process. Proteases implicated in
egress include the cytoskeleton-degrading malarial
proteases falcipain-2 and plasmepsin II, plus a family
of putative papain-like proteases called SERA. Recent
revelations have shown that activation of the SERA
proteases may be triggered by regulated secretion of
a subtilisin-like serine protease called SUB1. These
findings are discussed in the context of the potential
for development of new chemotherapeutics targeting
this stage in the parasite’s life cycle.
Introduction
All apicomplexan pathogens spend part of their life cycles
within the confines of a host cell or cyst. Plasmodium, the
causative agent of malaria, is no exception. At different
points in its life cycle the parasite finds itself residing within
either an oocyst on the basal side of the female Anopheline
mosquito mid gut wall, a vertebrate hepatocyte (or fibro-
blast) or a red blood cell (RBC). In the latter two cases the
parasite is not free within the host cell cytosol, but lies
within a membrane-bound parasitophorous vacuole (PV).
Following a period of repeated mitotic replication – the
length and extent of which varies considerably depending
on species and life cycle stage – the parasite exits from the
host cell in a process known as egress. Many details of how
the parasite makes its escape are obscure, but the accu-
mulated evidence indicates an important role for parasite
proteolytic enzymes. This review aims to critically summa-
rize this evidence in the expectation that it may provide
plausible future strategies in the search for improved
control of malaria and other pathologies caused by api-
complexan parasites. As a full appraisal of the molecular
role of proteases in egress cannot logically be considered
in isolation from the ultrastructural and physicomechanical
aspects of the process, this article comprises three sec-
tions: first, it briefly reviews what is known about the
mechanics of malaria parasite egress; second, it examines
the biochemical and genetic evidence implicating pro-
teases in egress; and finally it attempts to draw these
together into a collective model of how egress may be
regulated and targeted. Throughout, the main focus is on
egress of Plasmodium falciparum merozoites from the
blood-stage schizont, because of its particular significance
for chemotherapeutic control of severe clinical malaria and
because the majority of experimental work on egress has
been on this developmental stage.
The mechanics of egress
Live video microscopy has played a special role in studies
on egress. Real-time light microscopic visualization of
in vitro blood-stage egress and events leading up to it in
live parasites has been performed in the avian parasite
Plasmodium lophurae (Trager, 1956), in the simian para-
site Plasmodium knowlesi (Dvorak et al., 1975) and in
P. falciparum (Winograd et al., 1999; Wickham et al.,
2003; Glushakova et al., 2005). In all cases it was
observed that egress is a rapid – and therefore, by infer-
ence, highly regulated – event. Some debate exists over
the details, and the various studies have led to a number
of different if not necessarily mutually exclusive models
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for merozoite egress. These will not be discussed in detail
here, but they condense to the following four schemas. In
the first (Fig. 1A), merozoites are released in a cluster
through a single opening in the schizont, leaving behind a
membranous ‘ghost’ comprising the breached PV mem-
brane (PVM) and RBC membrane (Winograd et al.,
1999). Because the residual cytosol of this structure was
observed to persist for an extended period after merozoite
release, it was proposed that the initial opening is likely a
result of localized fusion of the PVM and RBC membrane,
effectively creating a large pore to allow parasite exit. The
second model (Fig. 1B), which can almost be viewed as
the diametrically opposite scenario, is that egress is quite
literally an explosive event, in which the mature parasit-
ized cell undergoes a short-lived increase in intracellular
volume before its sudden rupture, scattering the free
merozoites away from the site of rupture and leaving
behind vesiculated fragments of the separate host cell
and PV membranes (Glushakova et al., 2005). The third
model, referred to here as the ‘inside-out’ model, pro-
poses that egress involves two distinct stages in which
degradation of the PVM occurs prior to RBC membrane
rupture (Fig. 1C). Evidence for this derives from the use of
transgenic P. falciparum clones stably expressing green
fluorescent protein (GFP) either exclusively in the PV
lumen or in the RBC cytosol. Irrespective of its previous
location, the GFP marker was observed to relocalize to fill
the entire infected cell late in schizogony (Wickham et al.,
2003), interpreted as a result of PVM breakdown just prior
to eventual egress. In the last model, referred to here as
the ‘outside-in’ model, a two-stage process is again
postulated. Here, however, the first step in egress is dis-
ruption of the RBC membrane (Fig. 1D), releasing clus-
ters of merozoites still surrounded by an intact PVM which
is subsequently degraded in an exoerythrocytic event
(Salmon et al., 2001; Soni et al., 2005). Importantly,
these PVM-enclosed merozoite structures (PEMS) were
detected by Salmon et al. at low frequency in regular
P. falciparum cultures, suggesting that they represent a
normal, short-lived egress intermediate. This last model is
not directly supported by real-time microscopic evidence,
but by other data described below.
Electron microscopy (EM)-based ultrastructural analy-
ses cannot detect subtle time-dependent effects, but they
have a place in investigating the mechanistic basis of
egress. Both Langreth et al. (1978) and Aikawa (1971)
noted that intact, highly mature blood-stage schizonts
occasionally lack a discrete PVM, consistent with the
above-described ‘inside-out’ model of PVM degradation
preceding RBC membrane rupture at egress. Immuno-EM
analysis of mature wild-type parasites with antibodies to
the PV-resident protein S-antigen reached a similar con-
clusion (Wickham et al., 2003); once again, it was noticed
that this protein relocalized to fill the entire luminal space
of the infected cell in mature schizonts.
It will be clear from the above that it is presently difficult
to draw hard and fast conclusions regarding the temporal
sequence of PVM and RBC membrane rupture at egress.
Intuitively, it would seem unlikely that blood-stage egress
should differ fundamentally from egress of other intracel-
lular stages; after all, why should the malaria parasite
invent the wheel twice? In this context, although relatively
little is known about the mechanics of egress in other life
cycle stages, recent elegant work by Heussler and col-
leagues has revealed some important parallels between
egress of blood-stage and liver-stage merozoites. Hepato-
cytes infected in vivo or HepG2 cells infected in vitro with
GFP-expressing transgenic clones of the rodent malaria
Plasmodium berghei eventually round up, detach from
neighbouring cells and die. This is concomitant with disap-
pearance of the PVM and release of the mature merozoites
into the host cell cytosol (Sturm et al., 2006; Sturm and
Heussler, 2007). This observation, very clearly detectable
in these relatively large cells, is again consistent with the
‘inside-out’ model for blood-stage egress described above.
Egress requires protease activity
Whatever the physicomechanical details of egress and
the temporal sequence of PVM and host cell membrane
Fig. 1. Current models of asexual blood-stage merozoite egress.
A. The membrane fusion model of Winograd et al. (1999).
B. The ‘explosive rupture’ model of Glushakova et al. (2005) in
which the schizont forms a short-lived ‘flower’ structure.
C. The ‘inside-out’ model (Wickham et al., 2003) in which PVM
breakdown precedes RBC membrane rupture.
D. The ‘outside-in’ model in which the RBC membrane is degraded
first, allowing release of merozoites surrounded by the PVM, which
is eventually degraded in an exoerythrocytic step (Salmon et al.,
2001; Soni et al., 2005).
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rupture, all except perhaps the fusion model invoke a
requirement for generalized destabilization of the two
membranes and host cell cytoskeleton to allow their even-
tual disruption. This notion has encouraged a search for
parasite-derived molecular mediators of egress. The ear-
liest documented evidence suggesting protease involve-
ment in egress came from a series of studies indicating
effects on egress and RBC invasion by P. knowlesi upon
treatment with a range of protease inhibitors including the
broad-spectrum serine and cysteine protease inhibitors
leupeptin and chymostatin (Banyal et al., 1981; Dutta and
Banyal, 1981; Hadley et al., 1983). Lyon and Haynes
(1986) showed that the presence of a mixture of leupep-
tin, chymostatin, antipain (a serine and cysteine protease
inhibitor) and pepstatin (an aspartic protease inhibitor) in
cultures of P. falciparum asexual blood stages resulted in
the accumulation of mature schizonts in which the normal
process of egress was blocked. Analysis by SDS-PAGE
and Western blot of these stalled forms, referred to as
‘protease inhibitor clusters of merozoites’ (PCM), revealed
defects in the proteolytic processing and shedding of a
range of parasite proteins, including fragments of a major
schizont surface protein now known as merozoite surface
protein-1 (MSP1). Shortly after this study, Delplace et al.
(1988) demonstrated that leupeptin alone could prevent
P. falciparum schizont rupture, concomitantly interfering
with the proteolytic processing of an abundant PV protein
called P126 (now known as SERA5 – see below). Exami-
nation by EM of the stalled schizonts showed that,
whereas rupture of the RBC membrane was prevented by
the leupeptin treatment, disintegration of the PVM had
taken place, releasing the mature merozoites into the
residual cytoplasm of the host cell. This important finding
provided the first evidence that rupture of the PVM and
RBC membranes is differentially sensitive to protease
inhibitors. Several more recent studies have built on that
work. Salmon et al. (2001) showed that formation of
PEMS in cultures could be substantially upregulated by
the presence of the epoxide-based cysteine protease
inhibitor E64, interpreted as indicating that PVM but
not RBC membrane rupture involves an E64-sensitive
protease. Removal of the E64-mediated block (by
washing) showed that the PEMs contained viable, inva-
sive merozoites. As E64 is effectively an irreversible
inhibitor, this is an unexpected finding, but was interpreted
by the authors as indicating continued biosynthesis of the
cysteine protease(s) targeted by the E64, eventually over-
coming the block in egress. A study by Soni et al. (2005)
reached a virtually identical conclusion, again demon-
strating that the presence of either leupeptin or E64 pro-
duced extracellular clusters of merozoites apparently
surrounded by a still-intact PVM. Using their GFP-
expressing clones, Wickham et al. (2003) effectively
replicated and extended the finding of Delplace and col-
leagues; they showed that a mixture of leupeptin and
antipain allowed PVM rupture while blocking RBC mem-
brane rupture, whereas E64 treatment selectively blocked
PVM rupture but allowed RBC membrane degradation. In
a different approach, Gelhaus et al. (2005) found that
treatment of schizonts with biotinylated dibenzyl aziridine-
2,3-dicarboxylate, an irreversible cysteine protease inhibi-
tor, prevented egress by blocking rupture of the RBC
membrane, though apparently allowing PVM rupture.
Sturm and Heussler (2007), in their examination of liver-
stage merozoite egress from P. berghei-infected HepG2
cells, found that treatment of the cells with E64 blocked
egress and clearly prevented the PVM degradation that
usually precedes egress in this system.
It will be evident that the above studies reach some-
times conflicting conclusions, although much of the con-
trary data (e.g. the different effects of leupeptin in different
studies) could in part be a result of experimental variables
such as different culture conditions and differences in the
age of the RBC used in the cultures. Notwithstanding this,
at least three common threads can be drawn from the
accumulated data. These are: that breakdown of the PVM
and host cell membrane are differentially regulated; that
both events are protease-dependent; and that PVM
rupture is an E64-sensitive process. Given the high speci-
ficity of E64 for cysteine proteases, this strongly impli-
cates one or more cysteine proteases in PVM rupture,
and at least one additional distinct activity in host cell
membrane rupture. What are the likely identities of
the responsible proteases, and how are their activities
regulated?
Candidate proteases mediating egress
A dual function for haemoglobinases?
Three general approaches have been taken to establish
the identity of proteases participating in egress: analysis
of the subcellular localization and substrate diversity of
known malarial proteases; gene disruption studies; and
the use of selective small compound inhibitors. Much of
the interest in malarial proteases has been driven by the
phenomenon of haemoglobin digestion by the blood-
stage parasite. While it is still unclear whether the primary
role of this huge catabolic effort is to provide a source of
amino acids for the growing parasite or simply to make
space for it inside the host cell, interfering with it is detri-
mental to parasite growth. Thus far, four P. falciparum
aspartic proteases – plasmepsins I, II, III (otherwise
known as histoaspartic protease, or HAP) and IV, plus
three papain-like cysteine proteases called falcipain-2, -2′
and -3 – have been implicated in haemoglobin digestion.
Digestion takes place within an acidic digestive vacuole
(see Rosenthal, 2002, for a review). The finding that, in
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addition to its haemoglobinase activity, plasmepsin II can
also digest the host RBC cytoskeletal proteins spectrin,
protein 4.1, and actin at neutral pH, and that the protease
can be detected in mature schizonts within the cytoplasm
of the infected RBC (Le Bonniec et al., 1999), raised the
possibility that plasmepsin II might be involved in host cell
membrane destabilization at egress. Similarly, falcipain-2
was demonstrated to be capable of digesting ankyrin and
protein 4.1 at neutral pH (Dua et al., 2001; Hanspal et al.,
2002), and a peptide based on the cleavage site in
ankyrin inhibited the activity of recombinant falcipain-2
and also inhibited parasite maturation and egress when
delivered into schizonts (Dhawan et al., 2003). In the
same study, falcipain-2 expression was detected in sub-
cellular locations external to the parasite, both in the PV
and in vesicular structures extending into the RBC
cytosol. These findings are all provocative, but need to be
assessed in the light of subsequent gene disruption
studies that have shown that neither plasmepsin II nor
falcipain-2 is essential in asexual blood stages, and the
knockout lines exhibit no egress phenotype (Omara-
Opyene et al., 2004; Sijwali and Rosenthal, 2004; Liu
et al., 2005; 2006; Sijwali et al., 2006). Furthermore, there
is no evidence that specific inhibitors of aspartic pro-
teases (such as pepstatin) inhibit egress when used
alone, and other gene disruption experiments have dem-
onstrated that plasmepsins I, IV and HAP, as well as
falcipain-1 and 2′, are all individually dispensable in
asexual blood stages. It is too early to rule out a role for
any of these enzymes in egress but the indications are
that, if they are involved, there must be a degree of
redundancy in the system. Finally, it remains unclear how
the activities of these enzymes might be controlled to
achieve the very tight temporal regulation implied by the
light microscopic studies described above, although an
endogenous inhibitor of falcipains has been identified that
could conceivably play a role in this (Pandey et al., 2006).
The enigmatic SERA family: PV-located potential
mediators of egress
The full power of reverse genetics was demonstrated by a
beautiful study on the role of a different putative protease
in egress of midgut sporozoites from oocysts in the mos-
quito vector. In an investigation of genes previously
shown to be upregulated during P. berghei midgut sporo-
zoite biogenesis, Aly and Matuschewski (2005) examined
the consequences of disruption of a gene they named
egress cysteine protease 1 (ecp1). As expected, the
knockout lines exhibited no phenotype during blood-stage
growth and the early stages of sporogony, but the result-
ing midgut sporozoites failed to egress from oocysts.
Phase microscopic examination of the ecp1(-) oocysts
showed that the trapped sporozoites moved in a continu-
ous circular motion inside the intact oocysts, in contrast
to mature wild-type oocyst sporozoites which adopted
a radially oriented, mostly motionless state within the
oocysts. Mechanical dissection of the ecp1(-) oocysts
showed that the freed sporozoites possessed normal
gliding motility but were completely non-infectious when
mechanically transmitted to mice, in contrast to wild-type
oocyst sporozoites which were infectious (albeit poorly
compared with the salivary gland sporozoite stage that is
naturally transmitted to the vertebrate host). The oocyst
wall is a two-layered structure, with an inner wall of para-
site origin and an outer, thicker wall derived from the basal
lamina of the insect midgut epithelium. Further examina-
tion of the ecp1(-) oocysts showed that they were struc-
turally different from wild-type oocysts, being refractory to
permeabilization with saponin. Although the subcellular
site of expression of ECP1 was not determined, and
ECP1 has not been demonstrated to possess protease
activity, the authors speculated that it might play a role in
degradation of the inner wall of the oocyst at egress.
Consistent with this, comparison by Western blot of
ecp1(-) and wild-type oocysts detected a difference in the
pattern of proteolytic processing of the circumsporozoite
protein (CSP), a dominant component of the inner oocyst
wall.
The above seminal findings – which proved that oocyst
rupture is not simply a passive consequence of parasite
replication – have profound implications for egress in
other life cycle stages. The P. falciparum orthologue of
ecp1, called SERA8, belongs to a family of nine genes,
eight of which (SERA1–8) are disposed in a tandem head-
to-tail array on chromosome 2, while SERA9 is on chro-
mosome 9. All the SERA gene products share a central
relatively conserved papain-like domain as well as N- and
C-terminal regions that contain a number of conserved
Cys residues (Miller et al., 2002). The first identified family
member, now known as SERA5, was originally named
P126, P140 or P113, because of its apparent molecular
mass on SDS-PAGE, or SERP or serine-rich antigen
because of the presence of a stretch of up to 37 consecu-
tive Ser residues near its N-terminus. SERA5 was first
described as an abundant PV-localized protein that
appeared in P. falciparum culture supernatants in a pro-
teolytically truncated form upon schizont rupture (Del-
place et al., 1985; Delplace et al., 1987), and that could
induce antibodies that either protected against blood-
stage infection in vivo (e.g. Perrin et al., 1984; Delplace
et al., 1988; Inselburg et al., 1991; Enders et al., 1992) or
interfered with egress or invasion in vitro (Chulay et al.,
1987; Lyon et al., 1989; Sugiyama et al., 1996; Fox et al.,
1997; Pang and Horii, 1998; Pang et al., 1999). Expres-
sion levels of the different family members varies consid-
erably in blood stages, with SERA5 and SERA6 (originally
called SERP H; Knapp et al., 1991) being the most
1928 M. J. Blackman
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abundantly transcribed and translated (Aoki et al., 2002;
Miller et al., 2002); indeed, proteomic analyses have indi-
cated that SERA5 is among the most abundant schizont-
stage parasite proteins (Lasonder et al., 2002; Le Roch
et al., 2004). Although all the SERA genes are transcribed
in asexual blood stages (Aoki et al., 2002; Miller et al.,
2002), gene-targeting experiments have shown that most
are dispensable; only SERA5 and SERA6 could not be
disrupted, suggesting these are essential in this life cycle
stage (Miller et al., 2002; McCoubrie et al., 2007). Of par-
ticular interest, while SERA6, 7 and 8 (cysteine-type)
possess a Cys residue at the position of the canonical
catalytic Cys, SERA1–5 and 9 (serine-type) have a Ser at
this position (Kiefer et al., 1996) and appear to form a
distinct phylogenetic group (Hodder et al., 2003; Bourgon
et al., 2004), perhaps suggesting a distinct function. Con-
sistent with this, although the total number of SERA genes
differs in different Plasmodium genomes, all those that
have been examined to date appear to contain at least
one each of the two SERA types (Hodder et al., 2003;
McCoubrie et al., 2007). An as yet unanswered question
is the significance of this catalytic residue substitution;
replacement with Ser of the active-site Cys in papain or
cathepsin L abolishes enzyme activity (Clark and Lowe,
1978; Coulombe et al., 1996), so on this basis it might be
predicted that the serine-type SERA proteins are pro-
teolytically inactive. On the other hand, one subfamily of
papain-like proteins, the silicateins, are demonstrably
hydrolases and also possess the Cys-to-Ser substitution
found in the serine-type SERA subgroup (Shimizu et al.,
1998; Cha et al., 1999; Muller et al., 2007; 2008). Further-
more, a recombinant, refolded form of the SERA5 papain-
like domain shows weak chymotrypsin-like activity
(Hodder et al., 2003). It remains likely that both the serine-
and cysteine-type SERA members do indeed mediate
proteolytic roles in the parasite.
SERA processing is temporally associated with egress
Independent of the P. berghei ecp1 study described
above, a number of observations on P. falciparum SERA
biology have triggered extensive speculation regarding
a possible role in promoting egress and subsequent
invasion. First, all the SERA gene products that have
been detected in blood stages – SERA3, 4, 5, 6 and
possibly 9 – are most highly expressed at schizont stage
and localize to the PV lumen (Delplace et al., 1987;
Knapp et al., 1989; 1991; Aoki et al., 2002; Miller et al.,
2002), putting them in the right place and at the right time
to partake in egress. Second, early studies noted a
remarkably close temporal association between the pro-
teolytic processing of SERA5 and blood-stage egress,
with several observing that whereas processed products
of the SERA5 precursor (referred to here as SERA5
P126) are abundant in culture supernatants following
schizont rupture, only the precursor could be detected in
unruptured schizonts. In contrast, only unprocessed
SERA5 P126 was released upon mechanical rupture of
mature schizonts (using saponin or freeze–thaw), indicat-
ing that SERA5 processing requires naturally mediated
egress and is not simply a spurious consequence of non-
specific release of degradative parasite proteases into
culture medium accompanying egress (Delplace et al.,
1985; 1987; 1988). This important point is returned
to below. Detailed examination of SERA5 processing,
including N-terminal sequence analysis of affinity-purified
processed products, showed that processing takes the
form of an initial cleavage at a site just N-terminal to the
papain-like central domain, followed by a second cleav-
age C-terminal to it (Fig. 2) (Debrabant et al., 1992; Li
et al., 2002a,b). The released central fragment, called
P56, is then further processed by C-terminal truncation to
the terminal P50 form which eventually accumulates in
culture supernatants. In contrast, the N- and C-terminally
derived processing fragments, called P47 and P18,
respectively, remain associated in a disulfide-dependent
manner and appear to bind to the surface of the released
merozoites (Li et al., 2002b; Okitsu et al., 2007). This
intriguing observation is supported by the finding that
antibodies to P47, but not to P50, interfere with RBC
invasion by the released merozoites (Sugiyama et al.,
1996; Fox et al., 1997; Pang et al., 1999); this may
explain the in vivo protection observed in the many
SERA5 immunization trials referred to above. One pro-
vocative interpretation of these findings is that SERA5 –
and perhaps the other SERA family members, as they all
share a similar overall structure – is a dual-function
protein, with a central domain that acts as a soluble pro-
tease and plays a role in egress, and terminal domains
that interact with partner proteins on the merozoite
surface and play a quite separate role in merozoite viabil-
ity following egress (Fig. 2).
SERA processing by SUB1: an activation event?
Most proteases are synthesized as inactive zymogens
that are converted to their active forms by proteolytic
cleavage, either in an autocatalytic intramolecular manner
or in trans. It therefore seems plausible to predict that
SERA5 processing represents an activation event. In an
elegant attempt to characterize the protease(s) respon-
sible, Li et al. (2002a) examined parasite extracts for pro-
teolytic activity capable of converting a recombinant form
of SERA5 P126 to polypeptide fragments resembling the
authentic initial P47 and P73 processing products. Such
an activity was detected; it was most abundant in schizont
stages, it was membrane-associated, requiring a non-
ionic detergent for efficient extraction, and it was sensitive
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to diisopropyl flurophosphate (DFP) but not to a range
of other protease inhibitors including another broad-
spectrum serine protease inhibitor, phenylmethylsulfonyl
fluoride (PMSF). This implicated it as an unusual serine
protease. Importantly, the recombinant SERA5 P126 used
for these experiments was stable in the absence of para-
site extracts, indicating it was incapable of autocatalytic
processing. Further investigation showed that a different
parasite activity might be responsible for conversion of
P73 to the P56 and P18 products (though these data were
less clear), while a third distinct, leupeptin- and E64-
sensitive protease was clearly involved in truncation of
P56 to P50 (consistent with the leupeptin sensitivity of this
step noted by Delplace et al., 1988).
These findings have been greatly clarified by a recent
study in which processing of SERA5 was shown to be
mediated by a subtilisin-like serine protease called
PfSUB1. Previous work had shown that this protease is
expressed in a membrane-associated form in schizont
stages, and had partly characterized its substrate prefer-
ence and inhibitor profile using recombinant PfSUB1
(Blackman et al., 1998; Sajid et al., 2000; Withers-
Martinez et al., 2002). Using a transgenic parasite line
expressing epitope-tagged PfSUB1, Yeoh et al. (2007)
showed that PfSUB1 was expressed in an unusual set of
dense granule-like organelles (dubbed exonemes) from
which it is released, in a fully soluble form, into the PV
space just prior to egress. A selective PfSUB1 inhibitor
prevented egress and also blocked SERA5 processing,
suggesting a link between these events. Further exami-
nation showed that recombinant PfSUB1 correctly con-
verted purified, parasite-derived SERA5 P126 into the
P56 product, and an analysis of the processing sites using
multiple alignments and synthetic peptide substrates
demonstrated that PfSUB1 is also likely capable of pro-
cessing most of the other SERA family members at
equivalent sites; consistent with this, partially purified
parasite SERA4 and SERA6 were also processed by
recombinant PfSUB1 (Yeoh et al., 2007). In a separate
recent study (Arastu-Kapur et al., 2008), a chloroisocou-
marin selected in a screen for irreversible cysteine and
serine protease inhibitors that selectively blocked egress
Fig. 2. Model of SERA5 processing in the moments just prior to P. falciparum asexual blood-stage egress. The SERA5 P126 precursor is
located in the PV. Regulated discharge of PfSUB1 results in cleavage at two sites, releasing P56 which contains a central papain-like domain
(hatched) to play a proteolytic role in egress. The terminal P47 and P18 products of PfSUB1 processing remain in a disulfide-bonded complex
(blue line indicates disulfide bridge) and bind to the merozoite surface. P56 is eventually truncated by an unknown cysteine protease to
modulate its function, perhaps by inactivation. PfSUB1 likely processes SERA4 and SERA6, and perhaps other blood-stage SERA family
members, in a similar manner.
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was found to covalently label a major parasite protein that
was identified as mature PfSUB1. A different egress-
inhibitory compound, a dipeptide vinyl sulfone, covalently
labelled a distinct parasite protease, identified as
the cathepsin C-like dipeptidyl peptidase 3 (DPAP3).
However, inhibition of this appeared to affect maturation
or trafficking of PfSUB1 and other secreted parasite pro-
teins, so this may have been an indirect effect on PfSUB1
expression. As PfSUB1 has the unusual property of being
insensitive to a number of broad-spectrum serine pro-
tease inhibitors, including PMSF (Withers-Martinez et al.,
2002), it can safely be concluded that the serine protease
activity described above in the Li et al. (2002a) study in
fact corresponds to PfSUB1. The ‘membrane-associated’
characteristics of PfSUB1 in its exoneme-resident form
may be a result of these organelles being relatively
detergent-resistant. Taken together with all the above data
indicating a temporal link between SERA5 processing and
egress, these findings raise the remarkable possibility that
egress may be triggered by regulated discharge of
PfSUB1 into the PV to activate multiple members of the
SERA family. PfSUB1 appears to be an essential gene in
blood stages, with orthologues in all Plasmodium species
examined, and the above findings indicate it is a
‘druggable’ target. Interestingly, SERA orthologues were
detected in a recent proteomic analysis of liver-stage sch-
izonts (Tarun et al., 2008), so there is a distinct possibility
that the above postulated egress pathway may also
operate for this life cycle stage.
Why is SERA5 P56 truncated to P50 following the
PfSUB1 processing step? The fact that this is blocked by
leupeptin under conditions where RBC membrane rupture
is prevented (Delplace et al., 1988) raises the possibility
of a causal connection between these phenomena.
Proteolytic inactivation of protease activity is well docu-
mented (e.g. Samis et al., 2000; Crawley et al., 2005), so
if conversion of SERA5 P126 to P56 is an activation event
then could conversion of P56 to P50 represent a subse-
quent inactivation step or other functional modification
associated with RBC membrane rupture? This is just one
more unanswered question regarding this intriguing pro-
teolytic pathway. Identification of the cysteine protease
responsible would be a first step in addressing it.
Lessons from other intracellular pathogens
and conclusions
Many questions about malarial egress remain unresolved,
not least the fundamental issue of how proteases can
promote destabilization of the PVM and RBC membranes.
Simplistically, two broad mechanisms of protease action
may be imagined; proteases may act as indirect regula-
tors of egress by activating distinct effector proteins or
signal transduction pathways. Alternatively, proteases
may directly mediate the membrane and cytoskeletal
destabilization presumably required for egress, by
hydrolysis of integral membrane or cytoskeletal proteins
as described above for plasmepsin II and falcipain-2.
Other obligate intracellular pathogens may provide clues:
several intracellular bacteria and Leishmania use pore-
forming proteins or phospholipases for egress, and
Chlamydia egress is a two-stage process in which the first
step, breakdown of the intracellular inclusion vacuole, is
cysteine protease-dependent (Hybiske and Stephens,
2007; 2008). Rather little is known of the role of proteases
in egress of other apicomplexan genera, including the
highly experimentally tractable Toxoplasma gondii. It is
likely that future advances in these areas will shed useful
light on malarial egress.
In conclusion, the present indications are that egress of
different life cycle stages the malaria parasite involves
mechanistically conserved pathways and the action of at
least three essential proteases in the vertebrate host.
Arguably, all these represent viable future targets for
drugs designed to interfere with the critical step in the
parasite life cycle. The task now is to enhance our under-
standing of this pathway and exploit it in new approaches
to malaria control.
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